Advanced Biomed

Advanced Biomed is a Nevada-incorporated medical technology company headquartered in Tainan, Taiwan that is developing microfluidic biochip-based in vitro diagnostic platforms for cancer and personalized healthcare. The company closed a $6.56 million initial public offering on July 17, 2026 (disclosed via Form 8-K, accession 0001213900-26-079233), regaining Nasdaq listing compliance after a July 2025 notice that the bid price had closed below the $1.00 minimum-bid threshold for continued listing. Trading on Nasdaq under the symbol ADVB, the company had previously executed a 1-for-20 reverse stock split to consolidate its share count.